Parkinson's Disease
Conditions
Brief summary
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (\ 2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced dyskinesias. D-serine will be used as add-on therapy to on-going medications received by Parkinson's Disease patients. The rational for this study stems from observations made in pervious clinical trials with schizophrenia patients, in which it was demonstrated that D-serine adjuvant treatment resulted in:1)improvement of parkinsonian side effects induced by antipsychotic drugs and 2) improvement of depression and negative (i.e apathy, blunted effects, anhedonia) symptoms which are similar to symptoms encountered in Parkinson's Disease. The study will have a crossover design in accordance to which each patient will receive, in random order D-serine and placebo for a 6 weeks period each. Thus, any participant will have the opportunity to receive the experimental treatment.
Interventions
DRUGD-serine (~2g/day)
Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\ 2g/day). Second arm : adjuvant treatment with placebo (\ 2g/day).
Sponsors
Herzog Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* PD diagnosis * ≥2 on UPDRS items 32,33 * receive treatment with L-dopa alone or in combination with other antiparkinsonian medications.
Exclusion criteria
* current or previous history of other neurological disorders * unstable medical conditions * renal pathology * pregnant female patients excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UPDRS scores | 6 weeks |
| PANSS scores | 6 weeks |
Countries
Israel
Outcome results
None listed